Resources for Researchers
Developing, characterizing, and refining animal models are key to advancing medical countermeasures for high-consequence pathogens.
The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.
The Duke University School of Medicine, Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) is one of the NIAID-supported Biocontainment Laboratories.
Biocontainment Laboratory—George Mason University National Center for Biodefense and Infectious Diseases
The George Mason University National Center for Biodefense and Infectious Diseases Biomedical Research Laboratory (BRL) is one of the NIAID-supported Biocontainment Laboratories. The RBL supports research programs in the National Center for Biodefense and Infectious Diseases focusing on host resp
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tulane University Regional Biosafety Laboratory (RBL) at The Tulane National Primate Research Center is one of the NIAID-supported Biocontainment Laboratories.
The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
Biocontainment Laboratory—University of Missouri Regional Laboratory for Infectious Disease Research (LIDR)
The University of Missouri Laboratory for Infectious Disease Research (LIDR) is one of the NIAID-supported Biocontainment Laboratories.
The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.
As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms u
Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.
This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.
Diagnostic and molecular imaging are important components of research studies, as they provide real-time, longitudinal, structural, and functional insights into disease processes that cannot be obtained by other laboratory tests.
The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
A common data model for sharing observational HIV data has been developed by the International epidemiology Databases to Evaluate AIDS (IeDEA). The IeDEA DES is used by the seven operational regions of IeDEA to exchange data with each other for collaborative research studies.
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
PathogenAR is an Augmented Reality application from the National Institute for Allergy and Infectious Diseases (NIAID). Explore interactive stories about pathogens and pathogenic disease using touch gestures or a Merge Cube Device.
The pathology and histology laboratories at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) work together to conduct comprehensive postmortem examinations on laboratory animals of a variety of species studied as models for high-consequence emerging human viral infections.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.